An observational study in COPD and Quadriceps Muscle Atrophy, sponsored by Groupe Hospitalier du Havre. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Groupe Hospitalier du Havre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre — 3 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Groupe Hospitalier du Havre.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, this one is the only one that started in 2025, is one of 5 observational ones, and was the 8th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre are open now, in 1 country. Recruiting first, the newest first:
Groupe Hospitalier du Havre · Sites in France
Ages 18+
Groupe Hospitalier du Havre
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 30 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 22 across the 5 interventional studies, 30 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Groupe Hospitalier du Havre is the lead sponsor of 22 studies on the registry; 6 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371754Groupe Hospitalier du HavreShear Wave Elastography of Intercostal Muscles for the Non-invasive Assessment of the Work of BreathinG | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A large amount of patients with COPD suffer from muscle dysfunction characterized by losses of muscle mass and strength. Studies have shown an association between a loss of quadriceps muscle mass and premature death.
This study aims to investigate the clinimetric properties of a simple quadriceps perimetry and ShearWave elastography to improve the monitoring of skeletal muscle function in patients with COPD.
Muscle dysfunction in COPD is characterized by reduced skeletal muscle mass and strength, particularly in the lower limbs. These systemic consequences of COPD play a key role in the course of these patients, through their impact on functional status, quality of life and increased mortality. Early detection and monitoring of muscular status in these patients could help improve management and limit the consequences of the disease.
Numerous studies show that variation in quadriceps mass has a significant relationship with premature mortality in this disease. The use of an indirect but simple and affordable measure: perimetric tape-measurement of thigh circumference, could help monitor quadriceps muscle mass in these patients on a regular and cost-effective basis. However, the clinimetric properties (validity, reliability, response to treatment) of this measurement need to be assessed to clarify its relevance.
On the other hand, ShearWave ® elastography (SWE) is a new method of measuring quadriceps stiffness. This measurement could provide additional information on muscle quality compared with conventional measures of strength or muscle trophicity. The potential added value of SWE ® for COPD patients has not yet been investigated. This tool would provide more precise indications of the state of the quadriceps, with the aim of improving the management of this pathology.
COPD patients completing a PR programme for 5 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo a pulmonary rehabilitation (PR) programme. On day 1, perimetry and ShearWave measurements of the quadriceps muscle will be provided. Supplementary assessments of quadriceps thickness, quadriceps strength with a handheld dynamometry, lean body mass (bioelectrical impedance), constant work-rate endurance test and HAD questionnaire will also be provided on day 1. The same measurements and questionnaire will be provided on the last day of the patient in the PR programme.
Also known as: Functional exercice capacity, Quality of life, Bioelectrical impedance, Quadriceps thickness, Quadriceps strength : maximal voluntary contraction
Perimetry of the quadriceps
Thigh circumference measured by a tape
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Quadriceps stiffness
ShearWave elastography of the quadriceps muscle
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Lean body mass
measured by bioelectrical impedance
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Functional exercise capacity
measured as the endurance time during a constant load endurance test using a cycloergometer or a treadmill
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Health-Related Quality of Life
measured by quality of life questionnaire (hospital anxiety and depression scale (HAD))
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Quadriceps thickness
measured by ultrasonography
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Quadriceps strength
measure of maximal voluntary contraction with handheld dynamometry
Time frame: At day 1 and after 5 weeks (at the end of the 5 weeks pulmonary rehabilitation program)
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
Time frame: Beginning after publication and ending 60 months following article publication.
Access criteria: For individual participant data meta-analysis. Proposals should be directed to yann.combret@gmail.com. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 16 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Groupe Hospitalier du Havre